Viewing Study NCT06844032


Ignite Creation Date: 2025-12-24 @ 9:44 PM
Ignite Modification Date: 2025-12-29 @ 10:52 PM
Study NCT ID: NCT06844032
Status: RECRUITING
Last Update Posted: 2025-02-28
First Post: 2025-02-19
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Predictors of Poor Prognosis in HFpEF
Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Organization:

Study Overview

Official Title: Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure with Preserved Ejection Fraction
Status: RECRUITING
Status Verified Date: 2025-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
Detailed Description: Heart failure with preserved ejection fraction (HFpEF) is a serious condition with an unfavorable prognosis.

The investigators aimed to evaluate in patients with HFpEF:

* the prognostic significance of standard resting hemodynamic parameters compared to key cardiac reserves;
* the prognostic significance of clinical parameters (sex, age, NYHA class, extra-cardiac diseases, therapy);
* the prognostic significance of biological markers of hemodynamic stress and biomarkers of inflammation and fibrosis;
* to identify independent predictors of adverse prognosis of HFpEF.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: